Romosozumab is a monoclonal antibody that inhibits the protein, sclerostin, thereby increasing bone formation and decreasing bone resorption in a patient with osteoporosis. It is typically indicated for postmenopausal women with osteoporosis with the highest risk of bone fractures. [1]. This article covers details of romosozumab for the treatment of osteoporosis in postmenopausal women.
Introduction: Osteoposteoporosis is the most prevalent clinical condition in women compared to men, especially in postmenopausal women, because menopausal conditions like hormonal changes, calcium deficiency, etc., affect the bone density in women and increases the risk of bone fractures [1]. In menopausal conditions, the normal bone cycle is impaired due to estrogen deficiency which results in increased bone resorption than bone formation. Also, osteoclastogenesis and osteoclast activity is reduced…
